Cell Cure Neurosciences
Cell Therapies for Neural Degenerative Diseases
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Cell Cure Neurosciences | 02/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis) | Biochemical: pharmacological drugs (Developing drugs) | 01/01/2005 | "11-50" |
Cell Cure Neurosciences is a biotechnology company developing cell therapies for retinal and neural degenerative diseases. The company's technology is based on human embryonic stem cells. Cell Cure is using these powerful stem cells to manufacture a particular cell type in the retina called the retinal pigment epithelial (RPE) cell.
Cell Cure's first product in development, OpRegen, contains hESC-derived RPE to treat age-related macular degeneration (AMD). OpRegen is being developed as a front-line therapy for the dry form of AMD, which affects approximately 90% of AMD patients. Cell Cure Neurosciences is currently conducting a phase-I/IIa clinical trial of OpRegen to treat the larger market of dry AMD, for which there is currently no FDA-approved therapeutic. The company has recently completed the construction of a cGMP manufacturing facility for the production of OpRegen and other cell therapy products.
Cell Cure is a fully owned subsidiary of California-based Lineage Cell Therapeutics, Inc. (formerly BioTime).